Navigation Links
Oncothyreon reports full year and fourth quarter 2007 financial results
Date:3/10/2008

ecrease reflects operating expenditures of $22.8 million in 2007 offset by $15.8 million in cash received under the Company's collaborative and contract manufacturing agreements. The decrease was also offset by the favorable effect of exchange rate fluctuations on cash and cash equivalents of $1.7 million and short-term investments of $1.9 million.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. The Company is providing this guidance as a convenience to investors and assumes no obligation to update it.

For 2008, Oncothyreon expects expenses to increase over 2007 as a result of increased manufacturing and process development activities for Stimuvax(R) and more advanced clinical development activity for the Company's small molecule drugs. The Company expects these expenses to be partially offset by increased revenue related to the purchase of Stimuvax clinical supplies by Merck KGaA. As a result, Oncothyreon anticipates that operating cash requirements for 2008 will be between $17 million and $19 million. The Company estimates that it currently has sufficient cash resources to last into the second quarter of 2009.

Business Update

Key achievements for Oncothyreon in 2007 included:

- Initiating a Phase 2 trial of PX-12 in patients with advanced

pancreatic cancer.

- Initiating the START trial, a Phase 3 trial of Stimuvax in patients

with Stage III non-small cell lung cancer, in partnership with

Merck KGaA.

- Successfully manufacturing Stimuvax vaccine and placebo for the START

trial.

- Filing an IND and initiating a Phase 1 trial of PX-478 in patients

with advanced solid tumors or lymphomas.

- Signing amended and restated collaboration and supply agreements with

Merck KGaA for Stimuvax, providing for new, near-term milestones, the

first of which was received
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
2. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
3. Oncothyreon launches new corporate website
4. Oncothyreon to present at BIO CEO & Investor Conference
5. Oncothyreon highlights corporate and clinical objectives for 2008
6. Biomira announces plan to change name to Oncothyreon
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 This report is a ... industry. For an overview analysis, the report introduces ... chain structure, industry overview, policy analysis, and news ... has witnessed rapid development with key manufacturers ... This report mentions quartz tubing upstream raw materials ...
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the next step in its ... bio-analytics solutions provider with the naming of current Chief ... Chief Executive Officer, while current Chairman of the Board ... serve as Chairman. These changes are effective January 1, ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... Nerve Repair Discussed at American Society of Plastic Surgeons ... ... With the debut of NBC,s,"Bionic Woman," the notion of a bionic ... is getting closer to reality,as reconstructive plastic surgeons perform quality-of-life-enhancing,peripheral nerve ...
... 26 /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX, FSE: "HBP") today ... During the 2007 fiscal year, the Company continued ... pre-clinical (L-DOS47),development programs. The following are selected highlights during ... - Topical Interferon Alpha-2b, ...
... the first to demonstrate how an electron,s spin can ... engineers from the University of Delaware and Cambridge NanoTech ... a marathon distance in the world of microelectronics-- through ... silicon--the workhorse material of present-day electronics--now can be harnessed ...
Cached Biology Technology:Creating the Bionic Woman: Making Nerves Spring Back to Life 2Creating the Bionic Woman: Making Nerves Spring Back to Life 3Helix BioPharma Corp. announces fiscal 2007 results 2Helix BioPharma Corp. announces fiscal 2007 results 3Helix BioPharma Corp. announces fiscal 2007 results 4Helix BioPharma Corp. announces fiscal 2007 results 5Helix BioPharma Corp. announces fiscal 2007 results 6Helix BioPharma Corp. announces fiscal 2007 results 7Helix BioPharma Corp. announces fiscal 2007 results 8Helix BioPharma Corp. announces fiscal 2007 results 9Helix BioPharma Corp. announces fiscal 2007 results 10Helix BioPharma Corp. announces fiscal 2007 results 11Helix BioPharma Corp. announces fiscal 2007 results 12UD researchers race ahead with latest spintronics achievement 2
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... The fate of mature T lymphocytes might be a lot ... Center for Allergy and Immunology (RCAI) in Japan and La ... shows for the first time that mature CD4+ helper T ... and gain killing functions. The findings are reported ...
... one of the basics of neurobiology on its head ... already differentiated neuron into another within the brain. The ... maybe the brain is not as immutable as we always ... one can reprogram the identity of one neuronal class into ...
... extensive genomic study of the childhood cancer neuroblastoma ... forms of this disease. Contrary to expectations, the ... would suggest new targets for neuroblastoma treatment. Instead, ... how neuroblastoma tumors evolve in response to medicine ...
Cached Biology News:Mature T cells can switch function to better tackle infection 2Researchers turn one form of neuron into another in the brain 2Researchers turn one form of neuron into another in the brain 3Tumors evolve rapidly in a childhood cancer, leaving fewer obvious tumor targets 2